This is a past event. Registration is closed. View other DIA China events.
Vear LIANG, MD (Program Chair)
Senior Director, Disease Area Cluster Leader Generics, Shanghai Site Head, Safety Surveillance and Risk Management, Pfizer
Yuan YAO (Program Committee Member)
Head of Drug Safety, Merck China
Michael FORSTNER (Instructor)
- SESSION 9 - EVALUATION OF RISK MINIMISATION EFFECTIVENESS
- SESSION 2 - INTRODUCTION TO BENEFIT-RISK METHODOLOGIES
- SESSION 3 - EXAMPLES OF APPLICATION OF BENEFIT-RISK METHODOLOGIES
- SESSION 6 - TOOLBOX FOR PHARMACOVIGILANCE PLANNING
- SESSION 8 - OPTIONS FOR RISK MINIMISATION
Managing Director, Head of Risk Management & Business Process Management Practice, Mesama Consulting International, Switzerland
Jan PETRACEK (Instructor)
- SESSION 10 - BENEFIT-RISK MANAGEMENT PLAN – CASE STUDIES
- SESSION 11 - BENEFIT OPTIMISATION
- SESSION 12 - USE OF BENEFIT-RISK MANAGEMENT PLANS IN REGULATORY
- SESSION 1 - INTRODUCTION TO BENEFIT-RISK MANAGEMENT
- SESSION 4 - DESIGNING RISK MANAGEMENT SYSTEMS
- SESSION 5 - DOS AND DON’TS IN SAFETY SPECIFICATION
- SESSION 7 - EFFICACY SPECIFICATION AND FOLLOW-UP PLAN
CEO, PharmInvent, Czech Republic
President, PrimeVigilance, United Kingdom
Former Head of Risk Management, European Medicines Agency, EU
F. Richard XIA, MD (Instructor)
Director, Safety Risk Lead, Safety Surveillance and Risk
Management, Worldwide Safety & Regulatory, Worldwide
Research & Development, Pfizer Inc.